Loratadine OTC Switch Profitable For Payers And Consumers, Study Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
The Rx-to OTC switch of Claritin (loratadine) decreased cost to payers, whether changes to formulary status for antihistamines were made or not, according to a study in the American Journal of Managed Care. Mean copay costs were higher than OTC price, Sullivan et al. maintain.
You may also be interested in...
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement
Chattem’s Financing Strategy Keeps Door Open For Acquisitions
Chattem remains in the hunt for acquisitions because its preferred financing strategy continues to be attractive even with lending activity slowed worldwide, according to President and Chief Operating Officer Bob Bosworth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: